Another biosimilar to Herceptin
Note: this article provided by ONU Healthwise Pharmacy.
The US Food and Drug Administration (FDA) has approved another biosimilar to a drug that treats breast, stomach and esophageal cancer.
This biosimilar is called Kanjinti (trastuzumab-anns). The FDA approved it because it appeared to have no meaningful differences from Herceptin (trastuzumab), which has already been approved.
If a drug is a biosimilar to another drug, that means it is nearly identical to the other drug (called the reference product). According to the FDA's recent approval, Kanjinti is a biosimilar to Herceptin.
Similarly to Herceptin, the FDA approved Kanjinti to treat certain advanced cancers of the breast, stomach and esophagus. Kanjinti comes in the same dosage and strength as Herceptin.
When used to treat breast cancer, Kanjinti's potential side effects may include nausea, vomiting, fever, infusion reactions, infections, diarrhea, cough, headache, rash and fatigue, among others. When used to treat gastric cancer, Kanjinti's potential side effects may include anemia, fatigue, diarrhea, weight loss, fever and upper respiratory tract infections, among other side effects.
Kanjinti also comes with the same boxed warnings as Herceptin. These warnings point to potentially serious adverse effects tied to the use of this drug. These potential effects include a risk of serious cardiovascular problems, severe infusion reactions like anaphylaxis and acute respiratory distress and harm to an unborn baby.
The FDA granted approval of Kanjinti to Amgen and Allergan.
If you have cancer, talk to your health care provider about the best treatment options for your unique case.
Stories Posted This Week
Friday, June 6, 2025
Thursday, June 5, 2025
- Can you name the location of Pat's News Stand?
- June 9 ice cream social at Ada FUMC
- Land of Confusion: Is cannabis weed-ing out your ability to think clearly?
- Blacksmithing demonstrations on June 14 at Schumacher Homestead
- Content creators wanted for Ada Icon
- Crime Victim Services hosts Anti-Violence Teen Summer Retreat
- ACE Day coordinators seek projects for August 23
Wednesday, June 4, 2025
Tuesday, June 3, 2025
- Dwight Thomas Friesner served in the U.S. Army
- BlufftonIcon.com headlines for June 3
- Congratulations to Officer Michael Bollinger
- Chance R. Watkins worked at PlastiPak Packaging
- Public meetings scheduled for Ada committees, commissions
- Aggregation letters sent to Ada residents not enrolled in electricity programs
- Upcoming APL events, June 2-7
- Sign of the times